Patients who received single intravenous dose of tocilizumab were also more likely to leave the hospital or be off ventilator within a month, despite double the risk of additional infection, according to a new study.
Drug that calms ‘cytokine storm’ associated with 45 percent lower risk of dying among COVID-19 patients on ventilators
